Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study

Dextromethorphan 20 mg / quinidine 10 mg (DM/Q) was approved to treat pseudobulbar affect (PBA) based on phase 3 trials conducted in participants with amyotrophic lateral sclerosis or multiple sclerosis. PRISM II evaluated DM/Q effectiveness, safety, and tolerability for PBA following stroke, dementia, or traumatic brain injury (TBI).

https://www.pmrjournal.org/article/S1934-1482(18)30101-1/fulltext?rss=yes

Source: PM and R - February 22, 2018 Category: Rehabilitation Authors: Flora M. Hammond, William Sauve, Fred Ledon, Charles Davis, Andrea E. Formella Tags: Original Research Source Type: research